title: The mode of protein antigen administration determines preferential presentation of peptide-class II complexes by lymph node dendritic or B cells.
abstract: We have compared the capacity of dendritic cells (DC) and B cells to present peptide-class II complexes following administration of protein in adjuvant or in soluble form. Three different antigen-presenting cell (APC) populations were separated from draining lymph node cells from mice immunized s.c. with hen egg-white lysozyme (HEL) in adjuvant or with adjuvant only followed by soluble HEL: DC (N418+, class II+, B220-, low buoyant density), large B cells (B220+, low buoyant density) and small B cells (B220+, high buoyant density). HEL peptide-class II complexes displayed by these APC were evaluated by their capacity to activate HEL-specific T hybridoma cells. Following immunization with HEL in adjuvant, DC are the only lymph node APC population expressing detectable HEL peptide-class II complexes. Conversely, after i.v. administration of soluble HEL in mice previously injected with adjuvant only, lymph node B cells are much more efficient than DC in presenting peptide-class II complexes to T cells. Therefore, different modes of protein antigen administration lead to selective expression of antigenic complexes by different APC populations. These data correlate with the observation that, unlike B cells, DC recruited in lymph nodes of mice injected with adjuvant only present in vitro processed protein antigen much less efficiently than synthetic peptides, probably as a consequence of their maturation in vivo.
authors.affiliation: Roche Milano Ficerche, Milano, Italy.
authors.forename: J C
authors.initials: JC
authors.lastname: Guéry
authors.forename: F
authors.initials: F
authors.lastname: Ria
authors.forename: F
authors.initials: F
authors.lastname: Galbiati
authors.forename: S
authors.initials: S
authors.lastname: Smiroldo
authors.forename: L
authors.initials: L
authors.lastname: Adorini
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D017951:Antigen Presentation; D000941:Antigens / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D002469:Cell Separation / Q000379:methods; D003713:Dendritic Cells / Q000276:immunology* / Q000378:metabolism; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000276:immunology* / Q000378:metabolism; D008198:Lymph Nodes / Q000166:cytology* / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009113:Muramidase / Q000276:immunology*; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology*; D012995:Solubility
chemical_list: D000941:Antigens; D000949:Histocompatibility Antigens Class II; D010455:Peptides; D009113:Muramidase